BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 25552367)

  • 1. Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
    Onstenk W; Kraan J; Mostert B; Timmermans MM; Charehbili A; Smit VT; Kroep JR; Nortier JW; van de Ven S; Heijns JB; Kessels LW; van Laarhoven HW; Bos MM; van de Velde CJ; Gratama JW; Sieuwerts AM; Martens JW; Foekens JA; Sleijfer S
    Mol Cancer Ther; 2015 Mar; 14(3):821-7. PubMed ID: 25552367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
    Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF
    Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
    Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
    Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
    Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
    PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response.
    Satelli A; Brownlee Z; Mitra A; Meng QH; Li S
    Clin Chem; 2015 Jan; 61(1):259-66. PubMed ID: 25336717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
    Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
    Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform.
    Guo W; Yang XR; Sun YF; Shen MN; Ma XL; Wu J; Zhang CY; Zhou Y; Xu Y; Hu B; Zhang X; Zhou J; Fan J
    Clin Cancer Res; 2014 Sep; 20(18):4794-805. PubMed ID: 25009297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonality of circulating tumor cells in breast cancer brain metastasis patients.
    Riebensahm C; Joosse SA; Mohme M; Hanssen A; Matschke J; Goy Y; Witzel I; Lamszus K; Kropidlowski J; Petersen C; Kolb-Kokocinski A; Sauer S; Borgmann K; Glatzel M; Müller V; Westphal M; Riethdorf S; Pantel K; Wikman H
    Breast Cancer Res; 2019 Sep; 21(1):101. PubMed ID: 31481116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
    Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
    Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system.
    Hosokawa M; Kenmotsu H; Koh Y; Yoshino T; Yoshikawa T; Naito T; Takahashi T; Murakami H; Nakamura Y; Tsuya A; Shukuya T; Ono A; Akamatsu H; Watanabe R; Ono S; Mori K; Kanbara H; Yamaguchi K; Tanaka T; Matsunaga T; Yamamoto N
    PLoS One; 2013; 8(6):e67466. PubMed ID: 23840710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.
    Lustberg MB; Balasubramanian P; Miller B; Garcia-Villa A; Deighan C; Wu Y; Carothers S; Berger M; Ramaswamy B; Macrae ER; Wesolowski R; Layman RM; Mrozek E; Pan X; Summers TA; Shapiro CL; Chalmers JJ
    Breast Cancer Res; 2014 Mar; 16(2):R23. PubMed ID: 24602188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
    Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
    Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
    Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
    BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The detection of EpCAM(+) and EpCAM(-) circulating tumor cells.
    de Wit S; van Dalum G; Lenferink AT; Tibbe AG; Hiltermann TJ; Groen HJ; van Rijn CJ; Terstappen LW
    Sci Rep; 2015 Jul; 5():12270. PubMed ID: 26184843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells.
    Nini A; Hoffmann MJ; Lampignano R; Große Siemer R; van Dalum G; Szarvas T; Cotarelo CL; Schulz WA; Niederacher D; Neubauer H; Stoecklein NH; Niegisch G
    Cytometry B Clin Cytom; 2020 Jul; 98(4):355-367. PubMed ID: 32212383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method.
    Chalfin HJ; Kates M; van der Toom EE; Glavaris S; Verdone JE; Hahn NM; Pienta KJ; Bivalacqua TJ; Gorin MA
    Urology; 2018 May; 115():82-86. PubMed ID: 29432873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low.
    Ring A; Mineyev N; Zhu W; Park E; Lomas C; Punj V; Yu M; Barrak D; Forte V; Porras T; Tripathy D; Lang JE
    Oncotarget; 2015 Dec; 6(42):44623-34. PubMed ID: 26556851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146.
    Mostert B; Kraan J; Bolt-de Vries J; van der Spoel P; Sieuwerts AM; Schutte M; Timmermans AM; Foekens R; Martens JW; Gratama JW; Foekens JA; Sleijfer S
    Breast Cancer Res Treat; 2011 May; 127(1):33-41. PubMed ID: 20379845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.